L-DOPA sodium
Based on 35 publication(s) in Google Scholar
L-DOPA (Levodopa) sodium is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA sodium can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA sodium has anti-allodynic effects, and can be used for Parkinson's disease research.
For research use only. We do not sell to patients.
- Purity: 99.95%
- CAS No.: 63302-01-2
- Formula: C9H10NNaO4
- Molecular Weight:219.17
-
Storage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications Citing Use of MedChemExpress (MCE) L-DOPA sodium
More- Adv Sci (Weinh). 2025 Apr 13:e2413376. [Abstract]
- Adv Sci (Weinh). 2024 Aug 19:e2403058. [Abstract]
- Carbohydr Polym. 2026 Jan 1:371:124492. [Abstract]
- Ultrason Sonochem. 2025 Nov:122:107636. [Abstract]
- Int J Biol Macromol. 2024 Aug 26;279(Pt 1):134952. [Abstract]
- Int J Biol Macromol. 2020 Jun 15;153:88-99. [Abstract]
- Phytomedicine. 2026 Apr:153:157963. [Abstract]
- Free Radic Biol Med. 2024 Aug 1:220:167-178. [Abstract]
- Biomed Pharmacother. 2024 Jun:175:116664. [Abstract]
- Antioxidants (Basel). 2022 Jul 2;11(7):1317. [Abstract]
- J Agric Food Chem. 2025 Oct 15;73(41):25991-25997. [Abstract]
- Food Biosci. 2025 Jul.
- Int J Pharm. 2025 Sep 15:682:125938. [Abstract]
- CNS Neurosci Ther. 2023 Oct;29(10):2925-2939. [Abstract]
- Nutrients. 2022 Nov 4;14(21):4678. [Abstract]
- PLoS Pathog. 2026 Mar 10;22(3):e1014040. [Abstract]
- Gene Ther. 2024 Nov;31(11-12):614-624. [Abstract]
- Comp Biochem Physiol C Toxicol Pharmacol. 2026 Jul:305:110517. [Abstract]
- ACS Omega. 2025 Jul 14;10(28):30397-30410. [Abstract]
- Exp Neurol. 2025 Mar 30:115232. [Abstract]
- J Inflamm Res. 2025 Oct 11:18:14185-14201. [Abstract]
- Mol Med Rep. 2020 Aug;22(2):733-738. [Abstract]
- Skin Res Technol. 2026 Mar;32(3):e70334. [Abstract]
- IBRO Neurosci Rep. 2021 Nov 27:12:1-11. [Abstract]
- Genes (Basel). 2023 May 2;14(5):1035. [Abstract]
- FEMS Yeast Res. 2021 Mar 4;21(1):foab001. [Abstract]
- J Solid State Electrochem. 2025 Jan 17.
- J Cosmet Dermatol. 2025 Nov;24(11):e70510. [Abstract]
- Neurol Sci. 2025 May;46(5):2137-2148. [Abstract]
- Med Mycol. 2022 Nov 7;60(11):myac083. [Abstract]
- J Stroke Cerebrovasc Dis. 2024 Oct 26:108101. [Abstract]
- Chem Rev. 2022 Apr;39(2):327-335. [Abstract]
- CHIANG MAI J SCI. 2023 Jul 11.
- SSRN. 2024 Apr 19.
- Mater Express. 2021 Dec.
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
-
IHC
-
In Vivo Efficacy Study
-
WB
All Dopamine Receptor Isoforms
MoreAll Endogenous Metabolite Isoforms
More
Biological Activity
|
Human Endogenous Metabolite |
-
Animal Model:C57BL/6J mice (7-week-old)[3]
-
Dosage:20 mg/kg
-
Administration:Orally
-
Result:Reduced Rotenone-induced motor dysfunction.
-
Animal Model:Sprague-Dawley rats[4]
-
Dosage:10, 30, 50, 70, and 100 mg/kg
-
Administration:Orally
-
Result:Reverses tactile, cold and heat allodynia in neuropathic rat without any side effect.
Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment.
L-DOPA sodium can be used to create movement disorder models. In adult common marmosets, after oral administration of L-DOPA (20 mg/kg, 5 mg/kg) sodium, the Tmax in plasma is 30 minutes, and the Tmax in striatal extracellular fluid (ECF) is 60-90 minutes. The mean Cmax of L-DOPA sodium in plasma is 20.3 μM, while the mean Cmax in striatal ECF is 442.9 nM, representing about 2.2% of the plasma level[6].
Administration: 20 mg/kg • ip • once daily for 21 days
(2) Injection volume is 10mL/kg body weight.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 63302-01-2
-
Appearance Solid
-
Molecular Weight 219.17
-
Formula C9H10NNaO4
-
Color Light brown to khaki
-
SMILES
O=C([C@H](CC1=CC=C(C(O)=C1)O)N)O[Na]
-
Synonyms
Levodopa sodium; 3,4-Dihydroxyphenylalanine sodium
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (35)
-
Journal Impact Factor
-
Most Recent
-
Adv Sci (Weinh)
Massage-Mimicking Nanosheets Mechanically Reorganize Inter-organelle Contacts to Restore Mitochondrial Functions in Parkinson's Disease. [Abstract]2025 Apr 13:e2413376. PMID: 40223359
L-DOPA sodium purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Apr 13:e2413376. [Abstract]
Behavior analysis of pole test, rotarod test, suspension test, and forced swimming test after administration of L-DOPA, NanoMassage or saline. Mice were given an oral administration of 20 mg/kg L-DOPA on 4th day of MPTP administration and sacrificed on the 8th day.
-
Adv Sci (Weinh)
Ginsenoside Rg3 Restores Mitochondrial Cardiolipin Homeostasis via GRB2 to Prevent Parkinson's Disease. [Abstract]2024 Aug 19:e2403058. PMID: 39159293
L-DOPA sodium purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 Aug 19:e2403058. [Abstract]
Movement track and total distance travelled in the open field test, descent time in the pole test and time-to-fall in the rotarod test. Mice in the treatment groups intragastrically (i.g.) administered 20 mg/kg/d L-DOPA for 27 days.
L-DOPA sodium purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 Aug 19:e2403058. [Abstract]
Immunohistochemical staining of TH+ neurons. Mice in the treatment groups intragastrically (i.g.) administered 20 mg/kg/d L-DOPA for 27 days.
L-DOPA sodium purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 Aug 19:e2403058. [Abstract]
Quantification of TH+ neurons. Mice in the treatment groups intragastrically (i.g.) administered 20 mg/kg/d L-DOPA for 27 days.
-
Carbohydr Polym
Oral efficacy of structurally defined chondroitin sulfate Co-administered with SNAC in Parkinson's disease. [Abstract]2026 Jan 1:371:124492. PMID: 41198308 -
Ultrason Sonochem
Ultrasound-assisted enzyme extraction of Citri Exocarpium Rubrum (Juhong) polysaccharides and its structural characteristics and evaluation of improving Parkinson's disease through HDAC6/NLRP3 pathway. [Abstract]2025 Nov:122:107636. PMID: 41135205 -
Int J Biol Macromol
Schisandra chinensis (Turcz.) Baill neutral polysaccharides alleviate Parkinson's disease via effectively activating MCL-1 expression regulation of autophagy signaling. [Abstract]2024 Aug 26;279(Pt 1):134952. PMID: 39197630 -
Int J Biol Macromol
Contribution of phenoloxidase activation mechanism to Bt insecticidal protein resistance in Asian corn borer. [Abstract]2020 Jun 15;153:88-99. PMID: 32135253 -
Phytomedicine
Clematis Tangutica (Maxim.) Korsh. extracts promote melanogenesis via PKA/CREB activation and multi-cytokine inhibition: A novel dual targeting strategy for vitiligo therapy. [Abstract]2026 Apr:153:157963. PMID: 41720011 -
Free Radic Biol Med
Dopamine and its precursor levodopa inactivate SARS-CoV-2 main protease by forming a quinoprotein. [Abstract]2024 Aug 1:220:167-178. PMID: 38718952 -
Biomed Pharmacother
L-DOPA ameliorates hippocampus-based mitochondria respiratory dysfunction caused by GCI/R injury. [Abstract]2024 Jun:175:116664. PMID: 38678966 -
Antioxidants (Basel)
Antioxidative Role of Hygrophila erecta (Brum. F.) Hochr. on UV-Induced Photoaging of Dermal Fibroblasts and Melanoma Cells. [Abstract]2022 Jul 2;11(7):1317. PMID: 35883808 -
J Agric Food Chem
Validation of Insect Dopa Decarboxylase as a Potential Insecticide Target and Discovery of Selective Lead Compounds. [Abstract]2025 Oct 15;73(41):25991-25997. PMID: 41042682 -
-
Int J Pharm
Methylcobalamin-loaded ultra-flexible liposomes: a nanocarrier approach for modulating melanocyte homeostasis and addressing pigmentation imbalances. [Abstract]2025 Sep 15:682:125938. PMID: 40623604 -
CNS Neurosci Ther
Amphiregulin blockade decreases the levodopa-induced dyskinesia in a 6-hydroxydopamine Parkinson's disease mouse model. [Abstract]2023 Oct;29(10):2925-2939. PMID: 37101388
L-DOPA sodium purchased from MedChemExpress. Usage Cited in: CNS Neurosci Ther. 2023 Oct;29(10):2925-2939. [Abstract]
Amphiregulin (Areg) is highly expressed in the levodopa‐induced dyskinesia 6‐OHDA (4 μg; 4 weeks) Parkinson's disease mouse model. The Parkinson's disease group treated with a daily 12 mg/kg of levodopa for 15 days developed dyskinetic movement. On western blotting, this group further showed a significant increase of Amphiregulin protein expression relative to the Parkinson's disease group injected with normal saline only .
-
Nutrients
Neuroprotective Effects of Bifidobacterium breve CCFM1067 in MPTP-Induced Mouse Models of Parkinson's Disease. [Abstract]2022 Nov 4;14(21):4678. PMID: 36364939 -
PLoS Pathog
PDE4B deficiency aids macrophage differentiation and contributes to Cryptococcus neoformans brain infection. [Abstract]2026 Mar 10;22(3):e1014040. PMID: 41805786 -
Gene Ther
Targeting serum response factor (SRF) deactivates ΔFosB and mitigates Levodopa-induced dyskinesia in a mouse model of Parkinson's disease. [Abstract]2024 Nov;31(11-12):614-624. PMID: 39384937 -
Comp Biochem Physiol C Toxicol Pharmacol
Inactivation of the AMPKα/CncC/GPX4 axis mediates rotenone-induced ferroptosis in the silkworm (Bombyx mori) model. [Abstract]2026 Jul:305:110517. PMID: 41887387 -
ACS Omega
Dopamine Alleviated Diabetic Retinal Neurodegeneration through Protecting Retinal Ganglion Cells from Ferroptosis via the Nrf2/HO‑1 Signaling Pathway. [Abstract]2025 Jul 14;10(28):30397-30410. PMID: 40727724 -
Exp Neurol
Narirutin reduces microglia-mediated neuroinflammation by inhibiting the JAK2/STAT3 pathway in MPP+/MPTP-induced Parkinson's disease models. [Abstract]2025 Mar 30:115232. PMID: 40169108 -
J Inflamm Res
2025 Oct 11:18:14185-14201. PMID: 41103279 -
Mol Med Rep
2020 Aug;22(2):733-738. PMID: 32626944 -
Skin Res Technol
Enhanced Whitening Effect of the Formulations via Inhibition of Tyrosinase Activity by Combination of 4-n-Butylresorcinol, Licochalcone A and Glabridin at an Optimal Ratio. [Abstract]2026 Mar;32(3):e70334. PMID: 41853874 -
IBRO Neurosci Rep
Selenium reduces nociceptive response in acute 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-induced neurotoxicity. [Abstract]2021 Nov 27:12:1-11. PMID: 34927129 -
Genes (Basel)
2023 May 2;14(5):1035. PMID: 37239395 -
FEMS Yeast Res
Epigenetic regulation of virulence and the transcription of ribosomal protein genes involves a YEATS family protein in Cryptococcus deneoformans. [Abstract]2021 Mar 4;21(1):foab001. PMID: 33440003 -
-
J Cosmet Dermatol
KT-939: A Next-Generation Human Tyrosinase Inhibitor With Superior Efficacy for the Safe Management of Hyperpigmentation. [Abstract]2025 Nov;24(11):e70510. PMID: 41159291 -
Neurol Sci
Levodopa-synergistic CBT intervention improves Parkinson's disease with anxiety disorder by regulating the BDNF/PI3K/AKT pathway. [Abstract]2025 May;46(5):2137-2148. PMID: 39937424 -
Med Mycol
The RNA Helicase Ski2 in the Fungal Pathogen Cryptococcus neoformans Highlights Key Roles in Azoles Resistance and Stress Tolerance. [Abstract]2022 Nov 7;60(11):myac083. PMID: 36240494 -
J Stroke Cerebrovasc Dis
Dopamine receptor agonist pramipexole exerts neuroprotection on global cerebral ischemia/reperfusion injury by inhibiting ferroptosis. [Abstract]2024 Oct 26:108101. PMID: 39490461 -
Chem Rev
Effects of tea polyphenols on UVA-induced melanogenesis via inhibition of α-MSH-MC1R signalling pathway. [Abstract]2022 Apr;39(2):327-335. PMID: 35645678 -
-
-
Purity & Documentation
-
Data Sheet (278 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Hyland K, et al. Aromatic L-amino acid decarboxylase deficiency: diagnostic methodology. Clin Chem. 1992 Dec;38(12):2405-10. [Content Brief]
[2]. Merims D, et al. Dopamine dysregulation syndrome, addiction and behavioral changes in Parkinson's disease. Parkinsonism Relat Disord. 2008;14(4):273-80. Epub 2007 Nov 7. [Content Brief]
[3]. Perez-Pardo P, et al. Additive Effects of Levodopa and a Neurorestorative Diet in a Mouse Model of Parkinson's Disease. Front Aging Neurosci. 2018 Aug 3;10:237. [Content Brief]
[4]. Park HJ, et al. Anti-allodynic effects of levodopa in neuropathic rats. Yonsei Med J. 2013 Mar 1;54(2):330-5. [Content Brief]
[5]. M Lundblad, et al. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia. Exp Neurol. 2005 Jul;194(1):66-75. [Content Brief]
[6]. Jie Zhang, et al. Pharmacokinetics of L-dopa in plasma and extracellular fluid of striatum in common marmosets. Brain Res. 2003 Dec 12;993(1-2):54-8. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)